Ipamorelin: Selective GHRP Pharmacology, Receptor Biology, and Research Applications

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (5 amino acids) designed as a selective agonist of the growth hormone secretagogue receptor — specifically the GHS-R1a subtype, also known as the ghrelin receptor. Its sequence is: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Where Aib is alpha-aminoisobutyric acid, D-2-Nal is D-2-naphthylalanine, and the C-terminus carries an amide. These non-natural amino acid substitutions are engineering choices designed to confer resistance to proteolytic degradation and improve receptor selectivity over native ghrelin.

Ipamorelin was originally developed by Novo Nordisk as part of a GHRP optimization program. Unlike earlier GHRPs that triggered non-specific pituitary and adrenal effects, ipamorelin was engineered specifically to maximize GH release selectivity — a key property that distinguishes it from its pharmacological predecessors.

---

Receptor Biology and Mechanism

GHS-R1a Agonism

Ipamorelin acts at the GHS-R1a receptor, a G-protein-coupled receptor (GPCR) expressed most densely in the pituitary somatotrophs responsible for growth hormone synthesis and secretion. GHS-R1a activation triggers intracellular calcium release and downstream signaling that culminates in GH vesicle exocytosis.

The receptor is also expressed in the hypothalamus, hippocampus, and various peripheral tissues — the basis for ipamorelin's research relevance beyond simple pituitary physiology.

Selective GH Pulse

A key pharmacological characteristic of ipamorelin — and the reason it became a preferred GHRP research tool — is its selectivity for GH release compared to first-generation GHRPs:

GHRP-6 (hexapeptide): triggers GH release but also significantly elevates cortisol and prolactin via off-target receptor activity, complicating research designs that require isolated GH-axis measurements
GHRP-2 (hexapeptide): stronger GH stimulation than GHRP-6 but also with cortisol and prolactin elevation
Hexarelin: potent GHS-R1a agonist with cardiac receptor activity (CD36 binding) used in cardiac research, but broader receptor profile

Ipamorelin produces clean GH pulse stimulation with minimal off-target effects on cortisol, prolactin, TSH, or FSH at research-relevant concentrations. This selectivity makes it valuable when researchers need to study GH axis effects without the confounding variables introduced by stress-axis activation.

GH Pulse Profile

Ipamorelin produces a discrete, time-limited GH pulse following administration. Pharmacokinetic measurements in animal models place its plasma half-life at approximately 2 hours, with peak GH response typically observed within 15–30 minutes of administration. This short pulse profile contrasts with:

GHRH analogs (sermorelin, CJC-1295), which stimulate GH release through a different receptor (GHRHR) and longer timeframes
Long-acting GHRPs or hexarelin, which have extended activity profiles

The short half-life of ipamorelin, combined with its selectivity, makes it useful for studying pulsatile GH physiology — where the timing and amplitude of discrete GH pulses are research endpoints — rather than sustained GH elevation.

---

GHRH + GHRP Synergy

The pituitary has two distinct GH-release receptor systems:

1. GHRHR (Growth Hormone Releasing Hormone Receptor) — activated by GHRH and its analogs (sermorelin, CJC-1295, tesamorelin)

2. GHS-R1a — activated by ghrelin, ipamorelin, and other GHRPs

Research has documented that co-activation of both receptor systems produces a synergistic GH pulse substantially greater than either receptor alone. The mechanistic basis is that the two pathways converge on somatotroph calcium signaling through independent intracellular mediators (cAMP for GHRHR, IP3/DAG for GHS-R1a), and their simultaneous activation summates at the secretory level.

This synergy is the pharmacological rationale behind the commonly studied ipamorelin + CJC-1295 combination in GH-axis research. Ipamorelin provides the GHS-R1a input; CJC-1295 (or sermorelin) provides the GHRHR input.

For a detailed treatment of CJC-1295 combined with ipamorelin — including reconstitution protocols, study design considerations, and comparison of CJC-1295 DAC vs. No DAC variants — see the CJC-1295 & Ipamorelin research primer.

---

Research Applications

Pituitary Somatotroph Biology

Ipamorelin's primary research application is as a tool for studying somatotroph physiology. Because it selectively engages GHS-R1a without confounding cortisol or prolactin effects, it allows cleaner characterization of GH pulse dynamics than earlier GHRPs.

Aging and GH Axis Decline

Published literature has examined GHRP compounds in the context of somatopause — the age-associated decline in GH secretion and pulsatility. Ipamorelin has been used in rodent aging models to study whether restoring GH pulse amplitude and frequency produces measurable downstream effects on GH-dependent biological endpoints.

Appetite and Energy Metabolism

Because GHS-R1a is also expressed in hypothalamic regions involved in appetite regulation — including the arcuate nucleus — ipamorelin has been studied in models examining ghrelin-receptor-mediated appetite and energy homeostasis pathways. This application is distinct from its GH-releasing function and reflects the endogenous ghrelin receptor's role in feeding behavior research.

Cardiac and Muscle Models

The GHS-R1a receptor is expressed in cardiac tissue. Some published research has examined GHRP compounds in cardiac function models, though ipamorelin's cardiac receptor activity is more modest than hexarelin, which is the preferred GHRP for dedicated cardiac GHS-R models.

---

Comparison to Other GHRPs

Feature

Ipamorelin

GHRP-6

GHRP-2

Hexarelin

Structure	Pentapeptide	Hexapeptide	Hexapeptide	Hexapeptide
Primary receptor	GHS-R1a	GHS-R1a	GHS-R1a	GHS-R1a + CD36
GH selectivity	High	Moderate	Moderate	Moderate
Cortisol elevation	Minimal	Significant	Moderate	Moderate
Prolactin elevation	Minimal	Significant	Moderate	Moderate
Half-life	~2 hours	~15–30 min	~15–30 min	~30 min
Primary research use	GH-axis selectivity, pulsatile GH models	Benchmark GHRP	Potency comparator	Cardiac GHS-R, potency

---

Laboratory Handling

Ipamorelin is supplied as a lyophilized (freeze-dried) white powder. It reconstitutes readily in sterile water or bacteriostatic water. For research purposes, bacteriostatic water (0.9% benzyl alcohol) is standard when a reconstituted vial will be accessed multiple times over time.

Store lyophilized ipamorelin at −20°C in a sealed, dry container protected from light and moisture. Reconstituted solutions are typically stored at 2–8°C for short-term experimental use, or aliquoted and frozen at −80°C for longer-term storage. Repeated freeze-thaw cycles should be avoided.

See the reconstitution guide for standard lyophilized peptide reconstitution protocols and concentration calculation methods.

---

Frequently Asked Questions

Q: What makes ipamorelin different from other GHRPs?

The primary distinction is selectivity. Ipamorelin was specifically designed to maximize GH-axis signaling through GHS-R1a while minimizing engagement of cortisol and prolactin release pathways active with older GHRPs like GHRP-6. For research designs where isolated GH-axis measurement is required — without the stress-axis confounders of cortisol elevation — ipamorelin is the preferred GHRP.

Q: Why is ipamorelin always paired with CJC-1295 in published studies?

The GH secretagogue receptor (GHS-R1a) and the GHRH receptor (GHRHR) are two distinct pituitary receptor systems for triggering GH release. They work through different intracellular pathways and have been shown to produce synergistic effects when co-activated. Ipamorelin activates GHS-R1a; CJC-1295 activates GHRHR. The pairing allows researchers to study dual-pathway GH stimulation and produces larger GH pulse amplitudes than either compound alone — which is useful in research designs examining downstream GH-dependent effects.

Q: How does the ipamorelin + CJC-1295 combination compare to sermorelin + ipamorelin?

Both combinations engage the same GHRHR + GHS-R1a dual-receptor mechanism. The key difference lies in the GHRH component: sermorelin uses the native GHRH(1-29) sequence with a ~10–20 minute half-life, while CJC-1295 No DAC uses a stabilized variant with ~30 minutes, and CJC-1295 DAC extends to several days via the Drug Affinity Complex. The choice between them affects the temporal profile of GHRHR stimulation — whether the research design calls for a short GHRH pulse (sermorelin) or sustained GHRHR occupancy (CJC-1295 DAC).

Q: What is the molecular weight of ipamorelin?

Ipamorelin has a molecular weight of approximately 711.9 Da as the free base (C₃₈H₄₉N₉O₅). This is relevant for mass spectrometry verification on a Certificate of Analysis, where the [M+H]⁺ ion should appear near 712.9 Da.

---

Product Availability

Phase 1 Peptides stocks research-grade ipamorelin at 99%+ purity with batch-specific third-party laboratory documentation:

Ipamorelin — lyophilized, multiple dose sizes
CJC-1295 No DAC — frequently studied in combination with ipamorelin

---

Summary

Ipamorelin is a selective pentapeptide GHS-R1a agonist distinguished by its clean GH pulse pharmacology — minimal cortisol and prolactin co-release compared to earlier GHRPs — and a short plasma half-life that supports study of discrete pulsatile GH dynamics. Its primary research applications include isolated GH-axis pharmacology, pituitary somatotroph biology, and the study of GHRH + GHRP synergy when paired with CJC-1295, sermorelin, or other GHRH receptor agonists. For complete coverage of the CJC-1295 & Ipamorelin combination, see the CJC-1295 & Ipamorelin research primer.

For a side-by-side comparison of ipamorelin with GHRP-6, GHRP-2, and hexarelin across selectivity, potency, and research applications, see the GHRP Comparison overview.